Volver

Avicanna Inc

Ticker: AVCNF
Añadir al portafolio Análisis de cartera en 2min
Stock Small-cap
Capitalización
22,65 M $
Forward P/E
0,00
Profit margin
-9,97%
Revenue growth QoQ
-1,90%
Beta
0,33
0,08 $ -0,13%
Precio a fecha de 2026-09-21 · OTCQX

Rendimiento por período

Rendimientos acumulados
1 Month -14,24%
6 Months -36,88%
1 Year -56,17%
5 Years -36,52% p.a.-89,67%
Since inception -39,56% p.a.-97,13%
Rendimientos por año
YTD -51,30%
2025 -20,20%
2024 -24,25%
2023 +11,20%
2022 -63,48%
2021 -33,12%

Key stats

Market cap
22,65 M
Beta
0,33
52-week range
0.12 - 0.33
50-day MA
0,19
200-day MA
0,20
Section 1

Business overview

Company profile data from fundamentals.

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country Canada
Exchange OTCQX
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -27,01%
ROA -10,93%
Profit margin -9,97%
Operating margin 1,49%
Revenue/share TTM 0,24
Revenue TTM 25,34 M
EBITDA -3,19 M
Gross profit TTM 13,51 M
Beta 0,33

Valuation

Trailing P/E 0,00
Forward P/E 0,00
P/B 9,79
P/S 0,89
EV/EBITDA -1,68
EV/Revenue 1,11
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0,00
Quarterly earnings growth 0,00%
Revenue TTM 25,34 M
Reported quarters 19
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Shares outstanding 113,81 M
Shares float 82,07 M
Institutional ownership 0,00%
Insider ownership 26,94%
Short ratio 0,00

Details

Instrument metadata and source update timestamps.

Symbol AVCNF
Name Avicanna Inc
Asset type STOCK
Exchange OTCQX
Currency USD
Country USA
Code + exchange AVCNF.OTCQX
Fundamentals updated 2025-07-22

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.